Skip To Main Content

As the understanding of oncology progresses, it has become clear that the fight against cancer requires innovation from many angles. With a multifaceted approach to research and development, we are investigating a broad range of antitumor modalities, including individualized neoantigen-specific therapy, innovative bispecific antibodies, and novel antibody drug conjugates.

In the continued pursuit of truly personalized healthcare, we aim to improve specificity across all development platforms, to further identify the right approach for the right patient, and to transform the way cancer is treated in areas of unmet clinical need. 

 

Antibody Drug Conjugates

Antibody Drug Conjugates

See the science behind Genentech's continued development of antibody drug conjugates (ADCs) and the potential of delivering highly potent cytotoxins directly to malignant B cells and other tumors.1,2

Individualized NeoAntigen Specific Immunotherapy (iNeST)

Individualized Neoantigen-Specific Immunotherapy (iNeST)

Learn more about the potential of inducing antitumor immune responses through our investigational Individualized NeoAntigen Specific Immunotherapy (iNeST).3

Monoclonal Antibodies

Monoclonal Antibodies

Read more about our diverse approaches to transforming the innate ability of antibodies into potential therapeutic agents against cancer.4

Small Molecules

Small Molecules

Read more about our continued research in targeting intracellular tumor mechanisms to interrupt pathway dysregulation.5,6

Bispecific Antibodies

Bispecific Antibodies

Discover our unique bispecific antibody design technologies and the innovative method of harnessing the immune system to fight cancer through the simultaneous binding of T cells and tumor-cell antigens.7,8

    • Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089.

      Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089.

    • Polson AG, Yu S-F, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616-623.

      Polson AG, Yu S-F, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616-623.

    • Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222-226.

      Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222-226.

    • Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist. 2007;12:1084-1095.

      Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist. 2007;12:1084-1095.

    • Hanahan D, Weinberg D. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

      Hanahan D, Weinberg D. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

    • Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381-405.

      Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381-405.

    • Bacac M, Klein C, Umana P. Oncoimmunology. 2016;5:e1203498.

      Bacac M, Klein C, Umana P. Oncoimmunology. 2016;5:e1203498.

    • Bacac M, Fauti T, Sam J, et al. Clin Cancer Res. 2016;22:3286-3297.

      Bacac M, Fauti T, Sam J, et al. Clin Cancer Res. 2016;22:3286-3297.